Key Finding: Propolis, a natural compound produced by bees, has shown potent antiviral activity against the virus that causes chickenpox and shingles, including strains resistant to standard treatments.
Study Reveals Propolis as a Potent Antiviral Against VZV
A new study published in the journal Zoonoses has uncovered the significant antiviral potential of propolis (bee glue) against the varicella-zoster virus (VZV), the pathogen responsible for chickenpox and shingles.
Propolis Inhibits Virus Replication in Human Tissues
In laboratory experiments using human cell lines and tissue cultures, propolis demonstrated a strong, concentration-dependent ability to inhibit VZV replication. Notably, a 0.1% concentration of propolis was found to approach the antiviral efficacy of acyclovir, the current standard treatment.
How It Works
The study revealed that propolis operates through a unique mechanism. RNA sequencing showed that it alters host cell gene expression, specifically impacting pathways related to glycolysis, calcium signaling, and ferroptosis. Crucially, propolis was shown to inhibit viral RNA transcription and splicing.
A Key Advantage Over Existing Drugs
Propolis effectively inhibited an acyclovir-resistant strain of VZV (VZV-delTK), while acyclovir itself did not. This finding is significant because resistance to acyclovir, often caused by mutations in the viral thymidine kinase gene, is a growing clinical problem.
Implications for Future Treatment
The research suggests that propolis acts through a mechanism distinct from acyclovir, making it a promising candidate for further development as an anti-VZV agent, particularly for drug-resistant infections. The study calls for continued investigation into this natural compound as a potential therapeutic.
Methodological Notes:
- Experiments were conducted using ARPE-19 cells, human fetal skin, and dorsal root ganglia (DRG) tissues.
- Viral replication was measured using luciferase assays on a VZV strain engineered to express luciferase and GFP (pOka-Luc-GFP).
- An acyclovir-resistant mutant was generated using BAC (Bacterial Artificial Chromosome) technology.